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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.019During obstructive cholestasis, increased concentrations of bile acids activate ERK1/2 in hepatocytes,
which up-regulates early growth response factor 1, a key regulator of proinﬂammatory cytokines, such as
macrophage inﬂammatory protein 2 (MIP-2), which, in turn, exacerbates cholestatic liver injury. Recent
studies have indicated that IL-17A contributes to hepatic inﬂammation during obstructive cholestasis,
suggesting that bile acids and IL-17A may interact to regulate hepatic inﬂammatory responses. We
treated mice with an IL-17A neutralizing antibody or control IgG and subjected them to bile duct ligation.
Neutralization of IL-17A prevented up-regulation of proinﬂammatory cytokines, hepatic neutrophil
accumulation, and liver injury, indicating an important role for IL-17A in neutrophilic inﬂammation
during cholestasis. Treatment of primary mouse hepatocytes with taurocholic acid (TCA) increased the
expression of MIP-2. Co-treatment with IL-17A synergistically enhanced up-regulation of MIP-2 by TCA.
In contrast to MIP-2, IL-17A did not affect up-regulation of Egr-1 by TCA, indicating that IL-17A does not
affect bile acideinduced activation of signaling pathways upstream of early growth response factor 1. In
addition, bile acids increased expression of IL-23, a key regulator of IL-17A production in hepatocytes
in vitro and in vivo. Collectively, these data identify bile acids as novel triggers of the IL-23/IL-17A
axis and suggest that IL-17A promotes hepatic inﬂammation during cholestasis by synergistically
enhancing bile acideinduced production of proinﬂammatory cytokines by hepatocytes. (Am J Pathol
2013, 183: 1498e1507; http://dx.doi.org/10.1016/j.ajpath.2013.07.019)This studywas supported byNIH grantsDK073566 (B.L.C) andES017537
(J.P.L.). K.M.O. was supported by NIH training grant T32ES007255.Cholestatic liver diseases have many causes, such as familial
genetic disorders, xenobiotic exposure, autoimmune disease,
and tumors that disrupt bile ﬂow.1 A common feature of most
types of cholestatic liver disease is an elevation in proin-
ﬂammatory cytokines and hepatic accumulation of immune
cells.2e4 Studies in animal models have identiﬁed several
immune cell types and immunomodulatory cytokines that
are essential for the pathogenesis of cholestatic liver dis-
eases.3,5,6 The mechanisms that regulate hepatic inﬂammation
during cholestasis, however, are not fully understood. Eluci-
dation of these pathways could provide important insight
pertinent to the development of therapeutics for cholestatic liver
disease. Our recent studies indicate an important role for bile
acids in the development of inﬂammation during cholestasis.
In obstructive cholestasis, elevated biliary pressure dis-
rupts the integrity of intrahepatic bile ducts, resulting in
leakage of bile into the liver.7 As a result, concentrations of
bile acids, in particular taurine and glycine conjugates,
increase in the liver and serum in patients and in animalstigative Pathology.
.models.8,9 During bile duct ligation (BDL) in mice, serum
concentrations of bile acids exceed 3 mmol/L, with the
highest fraction of bile acids being conjugated with taurine.8
Modest increases in bile acid concentrations modulate
metabolic pathways in hepatocytes that promote detoxiﬁca-
tion of bile acids.10 However, pathologic concentrations of
bile acids trigger a strong inﬂammatory response in hepato-
cytes characterized by induction of diverse classes of cyto-
kines that promote inﬁltration of inﬂammatory cells,
including neutrophils, macrophages, and lymphocytes.11,12
Accumulating neutrophils extravasate from sinusoids and
adhere to hepatocytes, which stimulates their activation. The
activated neutrophils release toxic mediators that exacerbate
hepatocyte injury during cholestasis.2
We recently identiﬁed a bile acideactivated signaling
network that elicits the production of proinﬂammatory
Interaction of Bile Acids with IL-17Acytokines by hepatocytes. In these studies, pathologic con-
centrations of taurocholic acid (TCA) activated ERK1/2 and
up-regulated the transcription factor early growth response
factor 1 (Egr-1) in hepatocytes.11e13 Egr-1 then regulated
the production of several cytokines, chemokines, and ad-
hesion molecules that are crucial for neutrophil accumula-
tion and activation during cholestasis.11,12 In addition, bile
acids increased the expression of many proinﬂammatory
mediators in an Egr-1eindependent manner, suggesting that
bile acids promote inﬂammation by multiple mechanisms.11
Collectively, these studies indicated that bile acids are central
mediators of hepatic inﬂammation during cholestasis.
It was recently reported that the cytokine IL-17A con-
tributes to the hepatic production of proinﬂammatory medi-
ators and the progression of ﬁbrosis in BDL mice.14 IL-17A
is the best-characterized member of the IL-17 cytokine
family and is primarily produced and secreted by CD4þ T
helper (Th) 17 cells.15 Differentiation of murine naïve T cells
into Th17 effector cells is mediated by the cytokine trans-
forming growth factor-b with either IL-6 or IL-21.15,16 In
addition, IL-23 is required for the maintenance and stabili-
zation of Th17 cells.17 IL-17A signals via its receptor
complex, IL-17RA and IL-17RC, as a homodimer or as
a heterodimer with IL-17F.16 Through adaptor proteins, IL-
17A elicits the production of chemokines and cytokines
that promote neutrophil recruitment and, thus, an immune
reaction to extracellular pathogens.18,19 It was reported that
IL-17A-positive cells are increased in the livers of patients
with primary biliary cirrhosis.20 Similarly, it was demon-
strated that IL-17A levels are increased in mice subjected to
BDL.14 In this study, liver injury and ﬁbrosis were reduced in
IL-17RA knockout mice 3 weeks after surgery. Furthermore,
there were reduced levels of the cytokines tumor necrosis
factor a, IL-1b, and IL-6, indicating an important role for IL-
17A in the development of liver disease during cholestasis.14
Considering the importance of bile acids and IL-17A to
hepatic inﬂammation during cholestasis, a potential link
between these inﬂammatory mediators in the pathogenesis
of hepatocellular injury during cholestasis was investigated.
Accordingly, we tested the hypothesis that bile acids and the
IL-17 signaling axis interact to promote hepatic inﬂamma-
tion during cholestasis.
Materials and Methods
Animals
Studies were performed on 8- to 10-week-old male C57BL/
6 mice (The Jackson Laboratory, Bar Harbor, ME). All the
mice were maintained on a 12-hour light/dark cycle under
controlled temperature (18C to 21C) and humidity.
Food (Rodent Chow; Harlan-Teklad, Madison, WI) and tap
water were allowed ad libitum. For bile acid feeding, mice
were given an AIN-93M diet supplemented with 0.3% cholic
acid or an AIN-93M diet alone (Dyets Inc., Bethlehem, PA)
for 1 week. All the procedures on the animals were performedThe American Journal of Pathology - ajp.amjpathol.orgin accordance with the Guide for the Care and Use of
Laboratory Animals promulgated by the NIH.
Bile Duct Ligation
Mice were treated with 100 mg of antieIL-17A antibody
(clone 50104; R&D systems, Minneapolis, MN, and Bio X
Cell, West Lebanon, NH) or control IgG2A (clone 54447;
R&D systems and Bio X Cell) by i.p. injection 1 hour
before surgery.21 BDL was then performed on mice as
described previously.13 The mice were given an additional
50 mg of antieIL-17A antibody or control IgG on days 3
and 6 after surgery. Nine days after surgery, liver and blood
samples were collected from the mice for analysis.
Hepatocyte Isolation
Hepatocytes were isolated from mice by collagenase per-
fusion as described previously.13 Hepatocytes were plated in
Williams medium E (Invitrogen, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (Sigma-Aldrich, St.
Louis, MO) and penicillin-streptomycin (Sigma-Aldrich).
After 2 hours, hepatocytes were washed with 1 PBS and
were cultured in serum-free Williams medium E. Hepato-
cytes were treated with 10 ng/mL of recombinant mouse IL-
17A (R&D Systems), 100 nmol/L wortmannin (Cayman
Chemical Co., Ann Arbor, MI), 30 mmol/L SP600125
(Cayman Chemical Co.), or 10 mmol/L SB203580 (Cayman
Chemical Co.) in the presence or absence of 200 mmol/L
TCA (Sigma-Aldrich) as indicated.
Serum Chemical Analysis
Levels of serum alanine aminotransferase activity (Thermo
Scientiﬁc, Middletown, VA), total serum bilirubin (Pointe
Scientiﬁc Inc., Canton, MI), serum alkaline phosphatase
(Pointe Scientiﬁc Inc.), and total serum bile acids (colori-
metric total bile acids assay kit; Bio-Quant, San Diego, CA)
were measured using commercially available kits per the
manufacturer’s instructions.
Protein Analysis
IL-23 and macrophage inﬂammatory protein 2 (MIP-2)
proteins were quantiﬁed in culture medium by enzyme-
linked immunosorbent assay (ELISA) (BioLegend, San
Diego, CA). Total protein was collected from hepatocytes
lyzed with radioimmunoprecipitation assay buffer. Protein
was separated on a 4% to 20% polyacrylamide gel (Bio-Rad
Laboratories, Hercules, CA). Membranes were incubated
with either antiephospho-AKT (Thr308), anti-AKT, antie
phospho-JNK (Thr183/Tyr185), anti-JNK, antiephospho-
p38 (Thr180/Tyr182), or anti-p38 antibodies (Cell Signaling
Technology Inc., Danvers, MA). Membranes were then in-
cubated with the appropriate secondary antibody conjugated
with horseradish peroxidase. Protein bands were detected1499
Table 1 Primer Pair Sequences
Gene Forward Primer Reverse Primer
MIP2 50-CCTCAACGGAAGAACCAAAGAG-30 50-CTCAGACAGCGAGGCACATC-30
IL17A 50-CCGCAATGAAGACCCTGATAGA-30 50-TCATGTGGTGGTCCAGCTTTC-30
IL23 50-GTGACCCACAAGGACTCAAGGA-30 50-AGCAGGCTCCCCTTTGAAGAT-30
Cxcl5 50-GCTGGCATTTCTGTTGCTGTT-30 50-CGGTTAAGCAAACACAACGCA-30
Ccl7 50-AAGATCCCCAAGAGGAATCTCA-30 50-CAGACTTCCATGCCCTTCTTT-30
PAI1 50-AGTCTTTCCGACCAAGAGCA-30 50-ATCACTTGCCCCATGAAGAG-30
RPL13a 50-ACAAGAAAAAGCGGATGGTG-30 50-TTCTCCTCCAGAGTGGCTGT-30
ICAM1 50-AACAGTTCACCTGCACGGAC-30 50-GTCACCGTTGTGATCCCTG-30
Egr1 50-TGGGATAACTCGTCTCCACC-30 50-GAGCGAACAACCCTATGAGC-30
aSMA 50-GTTCAGTGGTGCCTCTGTCA-30 50-ACTGGGACGACATGGAAAAG-30
Col1a1 50-TAGGCCATTGTGTATGCAGC-30 50-ACATGTTCAGCTTTGTGGACC-30
Figure 1 Role of IL-17A in the development of hepatocellular injury
after BDL. A: IL-17A mRNA levels were quantiﬁed by real-time PCR in the
livers of mice subjected to BDL for the indicated times.*P < 0.05 versus
day 0. Mice were treated with either an antieIL-17A antibody or isotype
control. The mice were then subjected to BDL or sham operation. Alanine
aminotransferase (ALT) activity (B) and percentage area of liver necrosis
(CeE) were quantiﬁed 9 days after surgery. Scale bars: 100 mm. yP < 0.05
versus sham-operated mice; zP < 0.05 versus isotype control BDL mice.
Data are given as means  SEM.
O’Brien et alusing an electrochemiluminescence detection kit (GE
Healthcare, Buckinghamshire, UK).
Immunoﬂuorescence
Liver pieces were frozen in isopentane cooled in liquid
nitrogen for 8 minutes. Sections of frozen liver were cut and
ﬁxed in 4% formalin for 10 minutes. The sections were
incubated with a rabbit polyclonal antieIL-23A antibody
(Abnova Corp., Walnut, CA), a rat anti-mouse CD68 anti-
body (AbD Serotec, Raleigh, NC), or a rat anti-mouse F4/80
antibody (AbD Serotec) in 10% goat serum diluted with
PBS for 3 hours. The sections were then incubated with the
appropriate secondary antibody conjugated with Alexa
Fluor 594 (Invitrogen). CD68 and F4/80 immunostaining
were quantiﬁed and described previously.22
Immunohistochemical Analysis
Parafﬁn-embedded liver sections were incubated with rabbit
anti-rat polymorphonuclear leukocyte antibody (dilution
1:100) for 1 hour or rabbit antiea-smooth muscle actin (a-
SMA) antibody (dilution 1:100; Abcam Inc., Cambridge,
MA) overnight at 4C. Neutrophils were quantiﬁed by
counting the number of positively stained cells in twenty
200 ﬁelds per tissue section. The analysis was performed
in a blinded manner.
Real-Time PCR
TRIzol reagent (Sigma-Aldrich) was used to isolate RNA.
Contaminating DNA was removed by using the TURBO
DNA-free kit (Ambion, Austin, TX). cDNA was synthesized
as previously described.13 Relative mRNA levels were
measured using fast SYBR green reagent (Applied Bio-
systems, Foster City, CA) on a 7500 fast real-time PCR
system (Applied Biosystems). Primer sequences are shown in
Table 1. Primers used for these studies were intron spanning.
Statistics
Data are expressed as means  SEM. When two or more
groups were analyzed, a two-way analysis of variance was1500performed. Comparison between groups was performed by
using the Holm-Sidak method. The criterion for signiﬁcance
was a 95% conﬁdence, with P < 0.05.
Results
Neutralization of IL-17A Reduces Neutrophil
Accumulation and Liver Injury after BDL
It was previously shown that neutrophils contribute to hepatic
injury after BDL.2 Given that IL-17A is instrumental in
driving neutrophilic inﬂammation, we characterized theajp.amjpathol.org - The American Journal of Pathology
Table 2 Neutralization of IL-17A Does Not Affect Markers of Cholestasis
Measurement Control IgG sham AntieIL-17A sham Control IgG BDL AntieIL-17A BDL
Alkaline phosphatase (U/L) 146.7  2.2 155.4  14.3 973.6  142.5* 916.6  51.9*
Bilirubin (mg/dL) 0.1  0.1 0.07  0.04 16.8  1.2* 17.4  1.0*
Serum bile acid (mmol/L) 13.6  1.5 11.5  0.5 274.3  7.6* 277.0  10.9*
Data are given as means  SEM. The mice were treated with 100 mg of antieIL-17A antibody or control IgG. After 24 hours, the mice were subjected to BDL
or sham surgery. The mice were further treated with 50 mg of antieIL-17A antibody or control IgG 3 and 6 days after surgery. The mice were sacriﬁced 9 days
after surgery. Alkaline phosphatase, bilirubin, and total bile acid levels were measured using commercially available kits.
*Signiﬁcantly different from sham-operated mice (P < 0.05).
Figure 2 Effect of IL-17A neutralization on hepatic accumulation of
macrophages in the liver after BDL. Mice were treated with either an
antieIL-17A antibody or isotype control and then were subjected to BDL or
sham operation. Nine days after surgery, F4/80-positive macrophages were
identiﬁed in the liver by immunostaining in control IgG BDL mice (A) and
in antieIL-17A antibody BDL mice (B). In addition, isotype control BDL
livers (C) and antieIL-17A antibody BDL livers (D) were stained for CD68-
positive macrophages. Scale bars: 100 mm. E and F: The area of positive
staining was then quantiﬁed in sections of liver and expressed as a fraction
of the total area. *P < 0.05 compared with sham-operated control mice.
Data are given as means  SEM.
Interaction of Bile Acids with IL-17Aexpression of IL-17A in liver over time after BDL. IL-17A
mRNA levels did not increase until 5 days after BDL
(Figure 1A). This increase in expression peaked on day 7 and
remained elevated at 14 days. Next, we determined the role of
IL-17A in the development of hepatocellular injury and
neutrophilic inﬂammation after BDL. Mice were treated with
either an antieIL-17A antibody or control IgG. The mice
were then subjected to BDL or sham operation for 3 or 9
days. BDL caused an increase in serum alanine aminotrans-
ferase activity, which was reduced in mice treated with
antieIL-17A antibody (Figure 1B). Furthermore, neutrali-
zation of IL-17A decreased the area of liver necrosis in BDL
mice (Figure 1, CeE). Neutralization of IL-17A did not
affect hepatocellular injury 3 days after surgery (data not
shown), a time point before up-regulation of IL-17A
(Figure 1A).
To ascertain whether blocking IL-17A speciﬁcally
decreased neutrophil-mediated inﬂammation or instead
caused a reduction in cholestasis in general, the effect of
antieIL-17A on markers of cholestasis was investigated.
Levels of alkaline phosphatase, total bilirubin, and total bile
acids were increased in the serum of mice 9 days after BDL
(Table 2). Neutralization of IL-17A did not affect the
increase in these markers of cholestasis (Table 2).
Next, we tested the hypothesis that neutralization of IL-
17A prevents accumulation of inﬂammatory cells in the
liver after BDL. Macrophages were detected in the liver by
immunohistochemical (IHC) staining for F4/80 and CD68
(Figure 2, AeD). F4/80- and CD68-positive macrophages
increased in the livers of BDL mice treated with control IgG
(Figure 2, E and F). Neutralization of IL-17A, however, did
not affect the accumulation of macrophages in the liver
(Figure 2, E and F). In addition, neutrophil numbers
increased in the livers of BDL mice treated with control IgG
(Figure 3). In contrast to macrophages, neutralization of IL-
17A decreased neutrophil numbers after BDL (Figure 3).
Cytokine Gene Expression Decreases in
AntieIL-17AeTreated BDL Mice
Because IL-17A neutralization decreased hepatic accumu-
lation of neutrophils, we investigated the expression of
cytokines and adhesion molecules on neutralization of IL-
17A in BDL mice. Hepatic mRNA levels of MIP-2, Cxcl5,
Ccl7, plasminogen activator inhibitor-1, and intercellularThe American Journal of Pathology - ajp.amjpathol.orgadhesion molecule-1 (ICAM-1) were increased in mice
treated with control IgG and subjected to BDL for 9 days
(Figure 4). Neutralization of IL-17A in BDL mice attenu-
ated the increase in MIP-2, Cxcl5, Ccl7, and plasminogen
activator inhibitor-1 levels (Figure 4, AeD). In contrast,
ICAM-1 mRNA levels were unaffected by IL-17A neu-
tralization (Figure 4E).a-SMA and Type I Collagen Levels Are Unaffected by
Neutralization of IL-17A
a-SMA and type I collagen mRNA levels were increased to
a similar extent in BDL mice treated with either control IgG1501
Figure 3 Neutralization of IL-17A decreased hepatic neutrophil
numbers after BDL. Neutrophils were stained in sections of liver by IHC
staining. A: Section of liver from a mouse treated with isotype control and
subjected to BDL. B: Section of liver from a mouse treated with antieIL-17A
antibody and subjected to BDL. Positive cells appear red in the photomi-
crographs. Scale bars: 50 mm. C: Neutrophils were counted in sections of
liver. *P < 0.05 versus sham-operated mice; yP < 0.05 versus isotype
controletreated mice subjected to BDL. Data are given as means  SEM.
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Figure 4 Neutralization of IL-17A decreased the expression of pro-
inﬂammatory mediators after BDL. Mice were treated with antieIL-17A
antibody (gray bars) or control IgG (black bars) and were subjected to BDL or
sham surgery as detailed in Materials and Methods. Nine days after surgery,
mRNA levels of the proinﬂammatory mediators MIP-2 (A), Cxcl5 (B), Ccl7 (C),
plasminogen activator inhibitor-1 (PAI-1) (D), and ICAM-1 (E) were
measured by real-time PCR. *P< 0.05 versus sham-operated mice; yP< 0.05
versus BDL mice treated with control IgG. Data are given as means  SEM.
O’Brien et alor antieIL-17A (Figure 5, A and B). Similar to the mRNA
levels, a-SMA protein levels, detected by IHC analysis, and
collagen protein levels, detected by trichrome staining, were
not different between control IgGetreated mice and antie
IL-17Aetreated mice subjected to BDL (Figure 5, CeF).
IL-17A Synergistically Enhances TCA-Induced
Up-Regulation of MIP-2 mRNA in Primary Mouse
Hepatocytes
We previously demonstrated that TCA promotes proin-
ﬂammatory mediator production by hepatocytes, which is
important for inﬂammation in the liver during choles-
tasis.11e13 Considering that IL-17A is also important for
inﬂammation during cholestasis (Figures 3 and 4), we
investigated whether IL-17A affects bile acideinduced up-
regulation of inﬂammatory mediators by hepatocytes. We,
therefore, treated hepatocytes with IL-17A in the presence
or absence of 200 mmol/L TCA. IL-17A and TCA alone
increased MIP-2 gene expression in primary mouse hepa-
tocytes (Figure 6A). Co-treatment with IL-17A and TCA
synergistically enhanced the induction of MIP-2 mRNA
compared with treatment with IL-17A or TCA alone
(Figure 6, A and B). MIP-2 protein concentrations were
increased in the medium from hepatocytes treated with
either IL-17A or TCA (Figure 6C). Similar to MIP-2 mRNA
levels, co-treatment with IL-17A and TCA substantially
increased MIP-2 protein levels compared with hepatocytes
treated with either IL-17A or TCA alone (Figure 6C). We
previously demonstrated that up-regulation of MIP-2 in bile
acidetreated hepatocytes is Egr-1 dependent.11 Therefore,
we determined the effect of IL-17A on up-regulation of Egr-
1 by bile acids. As expected, TCA increased Egr-1 mRNA1502levels in hepatocytes (Figure 6D). IL-17A did not affect up-
regulation of Egr-1 by TCA (Figure 6D).
Unlike MIP-2, neutralization of IL-17A in mice did not
affect up-regulation of ICAM-1 in the liver after BDL
(Figure 4E). Accordingly, we determined whether IL-17A
would affect up-regulation of ICAM-1 in bile acidetreated
hepatocytes. Consistent with in vivo (Figure 4E), IL-17A
did not enhance TCA-induced up-regulation of ICAM-1
(Figure 6E).
Up-Regulation of IL-23 mRNA and Protein in Bile
AcideTreated Primary Mouse Hepatocytes
Because IL-23 promotes IL-17A production, IL-23 gene
expression was measured in wild-type mice subjected to
BDL over a 14-day period. IL-23 gene expression was
biphasic, with an initial peak at 6 hours followed by
a second peak at 5 days (Figure 7A). Previous studies have
demonstrated that serum and liver bile acid concentrations8
followed a similar time course as IL-23 mRNA levels,
thereby suggesting that bile acids may contribute to up-
regulation of IL-23 after BDL. Therefore, we tested the
hypothesis that TCA increases IL-23 production by primary
mouse hepatocytes. Treatment of hepatocytes with 200
mmol/L TCA increased IL-23 mRNA and protein levels
(Figure 7, B and C). Similar to its effects on MIP-2, IL-17Aajp.amjpathol.org - The American Journal of Pathology
Figure 5 Neutralization of IL-17A did not affect liver ﬁbrosis 9 days
after BDL. Mice were treated with antieIL-17A antibody (gray bars) or
control IgG (black bars) and were subjected to BDL or sham surgery as
detailed in Materials and Methods. Nine days after surgery, mRNA levels
of type I collagen (A) and a-SMA (B) were quantiﬁed. Data are given as
means  SEM. *P < 0.05 versus sham-operated mice. a-SMA protein was
detected in the livers of BDL mice treated with control IgG (C) or antieIL-
17A (D) by IHC analysis. Positive staining appears dark brown. Sections of
liver from BDL mice treated with control IgG (E) or antieIL-17A (F) were
stained with Masson trichrome. Scale bars: 50 mm.
Figure 6 Effect of IL-17A on up-regulation of inﬂammatory mediators
by TCA. A: Primary mouse hepatocytes were treated with 10 ng/mL of IL-
17A. The cells were then treated with 200 mmol/L TCA for the indicated
times. MIP-2 mRNA levels were measured by real-time PCR. *P < 0.05
versus vehicle-treated hepatocytes, yP < 0.05 versus TCA-treated hepato-
cytes, and zP < 0.05 versus IL-17Aetreated hepatocytes. B: Primary mouse
hepatocytes were treated with 10 ng/mL of IL-17A for 16 hours. The cells
were then treated with the indicated concentrations of TCA. MIP-2 mRNA
levels were measured by real-time PCR. xP < 0.05 versus hepatocytes
treated with vehicle and TCA. C: For quantiﬁcation of MIP-2 protein,
hepatocytes were treated with 10 ng/mL of IL-17A. The cells were then
treated with 200 mmol/L TCA for 12 hours. MIP-2 protein was quantiﬁed in
the medium by ELISA. *P < 0.05 versus vehicle-treated hepatocytes; {P <
0.05 versus hepatocytes treated with either TCA or IL-17A alone. Primary
mouse hepatocytes were treated with 10 ng/mL of IL-17A followed by
treatment with 200 mmol/L TCA. Egr-1 (D) and ICAM-1 (E) mRNA levels
were measured by real-time PCR. *P < 0.05 versus vehicle-treated hepa-
tocytes. Data are given as means  SEM.
Interaction of Bile Acids with IL-17Aenhanced up-regulation of IL-23 in hepatocytes by TCA
(Figure 7D).
Signal Transduction Pathways Involved in IL-23
Induction by TCA
In primary mouse hepatocytes, 200 mmol/L TCA activated
AKT (Figure 8A), c-Jun N-terminal kinases (JNK)
(Figure 8B), and p38 mitogen-activated kinase (p38)
(Figure 8C). Inhibition of PI3K/AKT or JNK signaling by
wortmannin or SP600125, respectively, attenuated up-
regulation of IL-23 by TCA (Figure 8, D and E). Inhibi-
tion of p38 by SB203580, however, enhanced IL-23
induction by TCA (Figure 8F).
Bile Acid Feeding Promotes Hepatic IL-23 Expression
To determine whether bile acids increase IL-23 expression
in vivo, mice were fed a diet containing 0.3% cholic acid or
a control diet for 1 week. This diet increased serum bile acid
concentrations, including TCA, by 1 week of feeding.23 IL-
23 mRNA levels were increased in the livers of mice fed the
0.3% cholic acid diet (Figure 9A). IHC staining for IL-23 in
the liver demonstrated increased IL-23 protein levels in
hepatocytes and sinusoidal cells (Figure 9, B and C).The American Journal of Pathology - ajp.amjpathol.orgDiscussion
IL-17A Contributes to Neutrophil-Dependent Liver
Injury during Obstructive Cholestasis
During obstructive cholestasis, neutrophils accumulate in
the liver, become activated, and exacerbate hepatocellular
injury.2 A recent study demonstrated that IL-17RA null
mice had reduced liver injury 3 weeks after BDL, sug-
gesting that IL-17A signaling is a prerequisite for hepatic
neutrophil accumulation during obstructive cholestasis.14 In
support of this, the present study demonstrated that
neutralization of IL-17A reduced neutrophil numbers in the
liver after BDL (Figure 3), which was associated with
a reduction in alanine aminotransferase levels and the area
of hepatic necrosis (Figure 1, BeE). Hepatic neutrophil
accumulation depends on up-regulation of various inﬂam-
matory cytokines and adhesion molecules.3,5,6 In the present
studies, neutralization of IL-17A attenuated up-regulation of1503
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Figure 7 Up-regulation of IL-23 in the liver and primary mouse hepa-
tocytes. A: Mice were subjected to BDL or sham operation. IL-23 mRNA levels
were measured in the liver. *P < 0.05 versus day 0. Primary mouse hepa-
tocytes were treated with 200 mmol/L TCA. IL-23 mRNA (B) and (C) protein
levels were measured. *P < 0.05 versus vehicle-treated hepatocytes. D:
Hepatocytes were treated with 10 ng/mL of IL-17A followed by treatment
with 200 mmol/L TCA. IL-23 mRNA levels were measured by real-time PCR.
*P< 0.05 versus vehicle-treated hepatocytes; yP< 0.05 versus hepatocytes
treated with either IL-17A or TCA. Data are given as means  SEM.
Figure 8 Role of signal transduction pathways in the up-regulation of
IL-23 by TCA. Hepatocytes were treated with 200 mmol/L TCA for 30
minutes. Western blot was used to detect phospho-AKT and total AKT (A),
phospho-JNK and total JNK (B), and phospho-p38 and total p38 (C).
Hepatocytes were treated with 100 nmol/L wortmannin (D), 30 mmol/L
SP600125 (E), or 10 mmol/L SB203580 (F) with or without 200 mmol/L TCA.
IL-23 mRNA levels were measured by real-time PCR. *P < 0.05 versus
vehicle treated hepatocytes; **P < 0.05 versus hepatocytes treated with
TCA in the absence of inhibitor. Data are given as means  SEM.
O’Brien et alseveral proinﬂammatory cytokines, including MIP-2, plas-
minogen activator inhibitor-1, Ccl7, and Cxcl5 (Figure 4,
AeD), suggesting that IL-17A promotes hepatic neutrophil
accumulation through up-regulation of proinﬂammatory
mediators that stimulate neutrophil migration to the liver
during obstructive cholestasis. Unlike a previous report,
however, we did not see a reduction in markers of liver
ﬁbrosis (Figure 5). One possible explanation for these
disparate ﬁndings is that we investigated a much earlier time
point after BDL (ie, 9 days versus 3 weeks in the previous
study).14
IL-17A Synergistically Enhances Up-Regulation of
Inﬂammatory Mediators in Bile AcideTreated
Hepatocytes
We recently demonstrated that bile acids up-regulate several
cytokines, chemokines, and adhesion molecules in hepato-
cytes in an Egr-1edependent manner.11 In addition, we
demonstrated that this process is important for neutrophil-
dependent liver injury during cholestasis. The present
studies demonstrate that IL-17A is also required for up-
regulation of inﬂammatory cytokines and neutrophil-
dependent liver injury similar to bile acids. In many cell
types, IL-17A alone is not a potent inﬂammatory cytokine.24
However, IL-17A modiﬁes the inﬂammatory response
produced by other cytokines, such as tumor necrosis factor
a and IL-6. For example, IL-17A synergistically enhances
up-regulation of proinﬂammatory mediators by tumor ne-
crosis factor a or IL-6 in alveolar type II cells, endothelial
cells, mesangial cells, astrocytes, and ﬁbroblasts.25e29 This
ﬁnding suggests that IL-17A may interact with other1504inﬂammatory mediators, such as bile acids, to produce
inﬂammation during cholestasis. The present results
demonstrate that IL-17A and TCA do interact to promote
robust production of inﬂammatory cytokines by hepato-
cytes. IL-17A alone modestly increased MIP-2; however,
MIP-2 production by hepatocytes was markedly increased
in the presence of IL-17A and TCA (Figure 6, AeC). Bile
acids activate ERK1/2 in hepatocytes, which stimulate up-
regulation of Egr-1. Egr-1 then regulates production of
MIP-2. Interestingly, IL-17A did not affect up-regulation of
Egr-1 (Figure 6D), suggesting that IL-17A does not enhance
up-regulation of MIP-2 by modulating bile acid signaling
upstream of Egr-1.
The synergistic enhancement of MIP-2 expression by IL-
17A and TCA may not only be important for obstructive
cholestasis but could be critical in other liver diseases,
including primary biliary cirrhosis and alcoholic hepatitis,
where IL-17A and bile acid concentrations are increased.30e32
In these diseases, IL-17A may promote modest hepatic in-
ﬂammation during the early stages. When these diseases
become severe and hepatic bile acid concentrations increase,
however, the interaction between IL-17A and bile acids
could severely exacerbate hepatic inﬂammation and disease
progression.
Bile acids may not only modify the response of hepato-
cytes to IL-17A but may also alter the response of other cell
types, in particular Kupffer cells. Studies have shown thatajp.amjpathol.org - The American Journal of Pathology
Figure 9 Up-regulation of IL-23 in the liver after bile acid feeding.
Mice were given either an AIN-93M diet supplemented with 0.3% cholic or
an AIN-93M diet alone. A: IL-23 mRNA was measured in the liver by real-
time PCR. Data are given as means  SEM. IHC staining was used to
detect IL-23 in sections of liver from mice fed an AIN-93M control diet (B)
or an AIN-93M diet supplemented with 0.3% cholic acid (C). Positive
staining for IL-23 appears red in the photomicrographs. The thick arrows
indicate IL-23 staining in hepatocytes. The thin arrow indicates the area of
IL-23 staining in the sinusoid. Scale bars: 50 mm. DAPI, which appears blue
in the photomicrographs, was used to stain nuclei.
Figure 10 Proposed mechanism of the interaction between bile acids
and the IL-23/IL-17A axis. Bile acids up-regulate MIP-2 and other cyto-
kines in hepatocytes by an Egr-1edependent mechanism. Bile acids also
up-regulate IL-23 in hepatocytes through AKT and JNK activation. IL-23
maintains Th17 cellular expansion and promotes the production of IL-
17A. Through an unknown signaling cascade, IL-17A synergistically
enhances TCA-induced production of MIP-2 and IL-23 by hepatocytes.
Enhanced production of IL-23 leads to the formation of a positive feedback
loop, which further ampliﬁes inﬂammation during cholestasis.
Interaction of Bile Acids with IL-17AIL-17A stimulates the production of inﬂammatory mediators
by Kupffer cells.14 In contrast to hepatocytes, however, bile
acids inhibit the production of inﬂammatory cytokines by
Kupffer cells.33,34 It has been proposed that this occurs through
activation of the bile acid receptor, TGR5.34 Accordingly, it is
possible that bile acids may inhibit IL-17Aeinduced produc-
tion of inﬂammatory cytokines by Kupffer cells during
obstructive cholestasis, which may explain the lack of tumor
necrosis factor a production by hepatic macrophages during
obstructive cholestasis, although concentrations of theThe American Journal of Pathology - ajp.amjpathol.orgmacrophage activators IL-17A and lipopolysaccharide are
increased.3 A similar effect could occur with other cell types
that express TGR5, including bile duct epithelial cells and
sinusoidal endothelial cells.34,35 The present in vitro data
demonstrate that hepatocytes express higher levels of inﬂam-
matory mediators in the presence of bile acids and IL-17A,
suggesting that in liver diseases, such as cholestasis, where
bile acid concentrations are increased, the production of
inﬂammatory mediators may shift from prototypical inﬂam-
matory cells toward hepatocytes. This type of inﬂammation
may be more resistant to commonly used anti-inﬂammatory
drugs, such as glucocorticoids, which may explain the resis-
tance of many types of cholestatic liver disease to anti-
inﬂammatory therapies.36
Bile Acids Are Novel Inducers of IL-23 by Hepatocytes
IL-23 is critical for the maintenance and stabilization of
CD4þ Th17 cells into effector Th cells.15 After BDL, IL-23
concentrations are increased, and this increase is required
for the production of IL-17A (Figure 7A).14 Interestingly,
the present studies demonstrated that the time course of IL-
23 up-regulation in the liver after BDL was biphasic and
identical to the time course of bile acid concentration
changes in the serum and liver (Figure 7A),8 suggesting that
bile acids may be important for up-regulation of IL-23 in the
liver. In support of this, TCA increased expression of IL-23
in primary mouse hepatocytes (Figure 7, B and C), and IL-
23 protein levels were increased in hepatocytes in mice fed
a diet containing 0.3% cholic acid (Figure 9). Furthermore,
up-regulation of IL-23 by TCA required JNK and AKT1505
O’Brien et al(Figure 8), indicating that bile acids could sustain and
exacerbate a Th17 response by stimulating the production of
IL-23, a process that was AKT and JNK dependent
(Figure 8, D and E). Similar to its effects on MIP-2, IL-17A
enhanced the TCA-induced production of IL-23 by hepa-
tocytes (Figure 7D), which could initiate a positive feedback
loop whereby bile acids stimulate the production of IL-23
by hepatocytes, which enhances IL-17A production by
Th17 cells. IL-17A then enhances the bile acideinduced
production of IL-23 and other inﬂammatory mediators by
hepatocytes. This process further enhances IL-17A
production and, ultimately, IL-23 and other inﬂammatory
cytokines that exacerbates hepatic inﬂammation and injury.
This process is illustrated in Figure 10.
The present results demonstrate that IL-17A synergisti-
cally enhances the bile acideinduced production of
inﬂammatory mediators by hepatocytes. Furthermore, we
demonstrated for the ﬁrst time that bile acids stimulate
hepatocytes to produce IL-23. Although these studies
suggest that the inhibition of IL-17A in patients with
cholestatic liver disease may be a logical therapeutic option,
systemic inhibition of IL-17A could negatively impact the
ability of patients to clear bacterial infections, which may be
particularly dangerous in patients with cholestasis who are
at risk for infections. Accordingly, elucidation of the
signaling mechanisms involved in the interaction between
IL-17A and bile acids may provide important insight into
speciﬁcally targeting the pathways involved in hepatic
inﬂammation during cholestasis without affecting the host
defense against invading pathogens.Acknowledgments
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